MICROBIOME, HIDDEN CHEMICAL SECRETS, BEING ACCESSED AT SCRIPPS PIER IN SAN DIEGO
Biosortia Pharmaceuticals is utilizing unique technologies to obtain the chemistry of previously unstudied microorganisms for drug discovery San Diego, California (November 8, 2016) – Biosortia Pharmaceuticals Inc. announces today that it is conducting an aquatic microbiome harvest from the Ellen Browning Scripps Memorial Pier on Tuesday, November 8 through Thursday, November 10. Microbiomes are being recognized
Continue ReadingReduce Risks and Increase Revenues by Building Platforms
Columbus, OH (May 16, 2016) – Ross Youngs is the person behind the US Department of Energy R&D project that led to the development of Biosortia’s drug discovery platform. The platform can identify useful drug-like chemicals from microorganisms in water continuously. It is a way to continuously assay different microorganisms and keep finding more and more
Continue ReadingBIOSORTIA CONTRACT GIVES RESEARCHERS ACCESS TO NATURAL PRODUCT CHEMISTRY FOR DRUG DISCOVERY EFFORTS
Columbus, Ohio (February 22, 2016) – Biosortia Pharmaceuticals announces today a contract with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) that gives the institution’s cancer researchers access to novel natural product chemistry for the purpose of discovering and developing cancer-fighting therapeutics.
Continue ReadingBIOSORTIA ANNOUNCES DRUG DISCOVERY RESEARCH AGREEMENT WITH ASTRAZENECA
Dublin, OH (July 15, 2013) – Biosortia Pharmaceuticals announced today a research agreement with AstraZeneca to screen Biosortia’s library of unique natural products derived from aquatic microbial consortia for evaluation against AstraZeneca’s therapeutic targets. The agreement includes the evaluation of partially refined mixtures as well as individual compounds. The aquatic environment is a rich source of
Continue ReadingBiosortia Tapping into Nature to Fill Early Drug-Discovery Void
By Emily Mullin, (July 09, 2013) – At a time when most of the biopharma industry has focused its preclinical research on screening synthetic compounds for their drug potential, Biosortia Pharmaceuticals is going back to nature to find promising compounds at the early stage of discovery. Dublin, OH-based startup Biosortia is harvesting the communities, or consortia,
Continue ReadingBIOSORTIA LAUNCHES INFECTIOUS DISEASE DRUG DISCOVERY TRIAL
Dublin, OH (June 11, 2013) – Dr. Nancy Sawtell, a professor, and researcher at Cincinnati Children’s Hospital Medical Center, will be using technology developed by Biosortia Pharmaceuticals of Dublin, Ohio in collaboration to potentially discover new biologically active natural products for the treatment of infectious diseases. The drug discovery research is focused on the evaluation of
Continue ReadingPresident & CEO Kurt Dieck And Founder Ross Youngs Will Present The Business And Science Of Biosortia Pharmaceuticals’ Disruptive Drug Discovery Technologies At CMC Event.
Dublin, Ohio (February 25, 2013) – On March 6th the Columbus Metropolitan Club at the Athletic Club of Columbus will host a lunch meeting where Biosortia Pharmaceuticals’ President & CEO Kurt Dieck along with founder Ross Youngs will share a look at the vast potential for a whole new world of biopharmaceutical drug discovery from aquatic
Continue ReadingBIOSORTIA CHASING DRUG DISCOVERIES FROM ALGAE HARVEST
By Carrie Ghose, (February 1, 2013) – The same mystery toxins from blooms of algae that sicken swimmers and kill fish also might be the source of drugs to fight cancer or drug-resistant bacteria. Biosortia Pharmaceuticals, a subsidiary of Marysville-based Algaeventure Systems Inc., is prospecting wild waterways for rare and previously unidentified chemicals that could be
Continue Reading